The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey
In December 2022, China classified COVID-19 as a category B infectious disease. This ended 2 years of close epidemiological surveillance of COVID-19. The objective of this questionnaire was to assess the infection status in the COVID-19 pandemic since December in Henan Province, China, and the preva...
Saved in:
Main Authors: | Cheng Zhou, Ran Jia, Jinqiu Yang, Tong Liu, Xiaoyan Liu, Lin Yang, Wenxia Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/cjid/4601882 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases
by: Tiantian Hu, et al.
Published: (2025-02-01) -
Effect of Ursodeoxycholic Acid Alone and Ursodeoxycholic Acid Plus Domperidone on Radiolucent Gallstones and Gallbladder Contractility in Humans
by: Ilyas Tuncer, et al.
Published: (2012-01-01) -
Ursodeoxycholic acid in complex treatment of metabolic syndrome
by: O. A. Tanchenko, et al.
Published: (2012-02-01) -
Ursodeoxycholic Acid and Atorvastatin in the Treatment of Nonalcoholic Steatohepatitis
by: Murat Kiyici, et al.
Published: (2003-01-01) -
Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)